AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02382549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Study NCT02382549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK inhibitor
Description: MEK Inhibitor
Study NCT03651726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THX-110 (dronabinol plus PEA)
Description: 2.5 mg dronabinol capsules and 400 mg PEA tablets
Study NCT03651726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
Study NCT02459041 — intervention group
Intervention type: OTHER
Intervention: Elastography, contrast enhancement
Description: Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors.
Study NCT02355756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxadilan
Study NCT02355756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00782028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Centering parenting/Group well child care
Description: Intervention families will receive well child care in a group format for the first 12 month of the child's life.
Study NCT00782028 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard Care
Study NCT02340494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Enhanced Education Tool
Description: The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
Study NCT02083419 — intervention group
Intervention type: DEVICE
Intervention: LVAD CRT
Description: The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
Study NCT01428297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle)
Study NCT01428297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPR277
Study NCT03811626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral rehabilitation
Description: Combination of clinical examination and neuropsychological and psychological tests
Study NCT01965184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Anger and Aggression
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 milligram per square meter (mg/m\^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
Study NCT04062760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard diuretic therapy
Description: The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
Study NCT04062760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early sequential nephron blockade
Description: After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value
Study NCT02975310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic polypectomy in clinic (EPIC)
Description: The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
Study NCT02975310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Sinus Surgery (ESS)
Description: The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
Study NCT02159326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas,BAY63-2521)
Description: multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
Study NCT02975310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: ESS will be performed under general anesthesia in the operating room
Study NCT02975310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local and topical anesthesia
Description: EPIC will be performed under topical and local anesthesia in a clinic setting
Study NCT00881842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
Study NCT01843569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: In Vitro maturation
Study NCT04206098 — intervention group
Intervention type: OTHER
Intervention: Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)
Description: Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
Study NCT01653834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphocyte harvesting & reinfusion
Description: Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
Study NCT01124734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
Study NCT01124734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
Study NCT04460313 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nasopharyngeal sample
Description: Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
Study NCT04460313 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stools collection or anorectal swab samples
Description: For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
Study NCT02034903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedings warmed with commercial warmer
Study NCT02269280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) Days 1 - 3
Description: Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
Study NCT02269280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
Study NCT02964286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Electric vibrating massager,SAMPO®
Description: The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
Study NCT01419704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoetic Stem Cell Infusion
Description: Enriched Hematopoetic Stem Cell Infusion
Study NCT00747617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human chorionic gonadotropin
Description: Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
Study NCT03431324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking about Mating Opportunities
Description: Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events.
Study NCT03431324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Mating-EFT Intervention
Description: This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate.
Study NCT00683475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
Study NCT00683475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.
Study NCT00683475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
Study NCT00683475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
Study NCT02625324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Evo Thoracic Stent Graft System
Description: Procedure: thoracic endovascular aneurysm repair (TEVAR)
Study NCT03148431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3002815
Description: Administered IV
Study NCT03148431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01865435 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cord blood sample
Study NCT02130479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management-Family Engagement
Study NCT02130479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study NCT00352755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical debulking with peritonectomy
Study NCT00352755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5FU
Study NCT00352755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Study NCT05294822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus
Description: Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
Study NCT02144558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: penile vibratory stimulation (PVS) or masturbation
Description: penile vibratory stimulation (PVS) or masturbation
Study NCT02269280 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care (BSC)
Description: Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
Study NCT02269280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) Days 1 - 5
Description: Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
Study NCT01528306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each
Study NCT01528306 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each
Study NCT04603625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postural management
Description: postural management in sitting position
Study NCT04603625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural management
Description: postural management in sitting position
Study NCT02471755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eelectro-acupuncture
Description: The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30\*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
Study NCT02471755 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Eelectro-acupuncture
Description: Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
Study NCT03516435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical stimulation
Description: Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
Study NCT03516435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal electrical stimulation
Description: Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
Study NCT00552942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic gastric bypass plus omentectomy
Study NCT01965184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy (SPT)
Study NCT03954197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hCG
Description: a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
Study NCT03954197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GnRH a
Description: a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
Study NCT03954197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GnRH a
Description: a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
Study NCT02543710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biomarker (ER/PR) guided lymphadenectomy
Description: Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with \<50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with \<50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 \<50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up.
Study NCT02543710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
Description: A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression.